Opus Genetics Says IDMC Issues Positive Recommendation To Continue As Planned In Phase 1/2 BEST1 Clinical Trial, Evaluating Opgx-BEST1 In Participants With Best Disease

Opus Genetics (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the Independent Data Monitoring Committee (IDMC) issued a positive recommendation to continue as planned in the Company's Phase 1/2 BEST1 clinical trial (BIRD-1), which is a multi-center, adaptive, open-label, dose-exploring study evaluating OPGx-BEST1 in participants with Best disease.